Genmab A/s share price logo

Genmab A/s Share Price

NASDAQ: GMAB

Large Cap

$27.98

+0.74

(+2.70%)

as on

Genmab A/s Stock Performance

as on March 11, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $27.59
    $28.16
    downward going graph

    1.39%

    Downside

    0.64%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $17.24
    $35.43
    downward going graph

    38.40%

    Downside

    26.63%

    Upside

    downward going graph

Genmab A/s share price movements today

Previous Close
$27.24
Open
$27.59
Volume
1.3M
Day's Low - High
$27.59 - $28.16
52 Week Low - High
$17.24 - $35.43

Genmab A/s Historical Returns

1 Month Return
-6.99 %
3 Month Return
-13.44 %
1 Year Return
+ 38.01 %
3 Year Return
-19.84 %
5 Year Return
-15.53 %

Genmab A/s Stock Fundamentals & Key Indicators

Check Genmab A/s market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$16.7B

EPS (TTM)

1.0934

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

-0.94%

PE Ratio (TTM)

17.69

Industry PE ratio

17.50525641025641

PEG Ratio

1.7494

EBITDA

1.3B

Revenue (TTM)

3.7B

Profit Margin

25.89%

Return On Equity TTM

17.54%

Genmab A/s Stock Valuation

Track how Genmab A/s P/E has moved over time to understand its valuation trends.

Genmab A/s in the last 5 years

  • Overview

  • Trends

Lowest (4.63x)

March 31, 2021

Industry (17.51x)

March 11, 2026

Today (17.69x)

March 11, 2026

Highest (64.13x)

September 30, 2021

LowHigh

Today’s Price to Earnings Ratio: 17.69x

Genmab A/s vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Genmab A/s with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
BUY$16.7B-15.53%17.6925.89%
BUY$42.9B125.47%138.888.45%
BUY$117.1B132.01%30.1232.94%
NA$34.9BNA121.895.37%
BUY$82.6B64.28%18.8331.41%

Stock Returns calculator for Genmab A/s Stock including INR - Dollar returns

The Genmab A/s stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

Genmab A/s investment value today

Current value as on today

₹1,43,297

Returns

₹43,297

(+43.3%)

Returns from Genmab A/s Stock

₹38,105 (+38.1%)

Dollar Returns*

₹5,192 (+5.19%)

Analyst Recommendation on Genmab A/s Stock

Based on 31 analysts

BUY

61.29%

Buy

29.03%

Hold

9.68%

Sell

Based on 31 analysts, 61.29% of analysts recommend a 'BUY' rating for Genmab A/s. Average target price of $37.65

Genmab A/s Share Price Target

Get share price movements and forecasts by analysts on Genmab A/s.

What analysts predicted

25.68%UPSIDE

Target Price

$37.65

Current Price

$27.98

Analyzed by

31 Analysts

Target

$37.65

Genmab A/s target price $37.65, a slight upside of 25.68% compared to current price of $27.98. According to 31 analysts rating.

Genmab A/s Stock’s Investor Sentiment and Interest

Search interest for Genmab A/s Stock has decreased by -22% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-22% versus previous 30 day period

Genmab A/s Quarterly Profit & Loss

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Total Revenue
674
685
87
112
824
903
103
5,861
1,022
6,722
Gross Profit
663
666
83
108
784
856
97
5,500
964
6,208
Operating Income
1,685
1,670
116
236
2,102
2,160
188
2,281
459
1,544
EBITDA
2,764
992
266
324
2,204
2,355
265
2,838
503
1,544
Interest Expense
8
6
4
19
18
54
5
57
3
279
Depreciation
85
-
13
173
112
115
16
16
18
21
Income Before Tax
2,670
926
249
307
1,719
3,602
244
2,680
482
349
Income Tax Expense
566
286
57
104
453
-243
49
551
81
152
Net Income
301
93
27
29
188
539
28
2,129
401
196
Net Profit Margin
44.65%
13.68%
31.84%
26.06%
22.85%
59.70%
27.27%
36.32%
39.24%
2.93%

Genmab A/s Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
257
376
460
798
1,652
1,279
2,063
2,412
3,019
23,728
Gross Profit
257
376
460
798
1,652
1,279
2,063
2,379
2,881
21,757
Operating Income
1,052
1,344
1,380
2,638
6,313
2,953
6,267
5,321
6,703
7,973
EBITDA
1,171
1,488
1,700
3,005
6,160
4,181
7,346
5,947
9,697
8,426
Interest Expense
0
2
0
7
10
13
21
27
120
389
Depreciation
-
69
87
139
259
248
362
295
413
71
Income Before Tax
1,130
1,063
1,611
2,859
5,904
3,918
6,945
5,637
9,164
7,679
Income Tax Expense
-56
-39
139
693
1,146
961
1,493
1,285
1,320
1,537
Net Income
168
175
224
322
777
449
775
637
1,100
6,142
Net Profit Margin
65.36%
46.65%
48.66%
40.37%
47.06%
35.13%
37.59%
26.42%
36.44%
25.89%

Genmab A/s Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Net Income
703
249
307
1,719
445
1,657
2,680
482
196
Operating Cash Flow
1,672
219
219
2,033
326
1,949
392
536
1,914
Investing Cash Flow
-442
-210
-1,270
224
113
-292
164
-54
-35,540
Financing Cash Flow
-22
-85
-440
-276
40
-88
-2,572
-21
33,356
Change in Cash
594
-77
-1,505
2,011
425
1,623
-2,046
465
-292

Genmab A/s Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
1,063
1,611
2,859
4,758
3,983
7,035
5,637
7,844
6,142
Operating Cash Flow
1,588
1,014
1,326
6,433
2,228
3,912
7,380
7,771
7,564
Investing Cash Flow
-667
-1,777
-1,983
-2,351
-961
-2,761
-1,282
-9,907
-35,993
Financing Cash Flow
214
-70
3,660
71
-420
-789
-606
-3,919
30,546
Change in Cash
1,040
-814
3,019
3,708
1,697
936
4,974
-5,009
2,200

Global Institutional Holdings in Genmab A/s

Funds
Holdings
Citadel Advisors Llc
0.58%
AllianceBernstein L.P.
1.78%
Brandywine Global Investment Mgmt LLC
0.23%
Northern Trust Corp
0.14%
Perpetual Ltd
0.13%

Genmab A/s News & Key Events

  • img

    Today's Timeline - 17 February

    Tue, 09:32 PM

    -

    Genmab publishes 2025 Annual Report, highlighting revenue growth and key product approvals.

    Wed, 00:16 AM

    -

    Genmab reports Q4 earnings, with 19% revenue growth and significant proprietary medicine sales increase.

    Wed, 01:45 AM

    -

    Genmab initiates share buy-back program, repurchasing up to 342,130 shares for 725 million DKK.

Insights on Genmab A/s

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 2 quarters, 1.02B → 6.72B (in $), with an average increase of 84.8% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 77.2% return, outperforming this stock by 99.1%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 35.5% return, outperforming this stock by 1.0%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 3 quarters, 2.12B → 196.98M (in $), with an average decrease of 66.0% per quarter

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 1 month, GMAB stock has moved down by -9.4%

About Genmab A/s

Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund.
OrganisationGenmab A/s
HeadquartersCarl Jacobsens Vej 30, Copenhagen, Denmark, 2500
IndustryHealth Technology
CEODr. Jan G.J. van de Winkel Ph.D.
E-voting on sharesClick here to vote

Key Management of Genmab A/s

Name

Title

Dr. Mijke Zachariasse Ph.D.

VP, Head of Antibody Research Materials & Director

Dr. Jan G.J. van de Winkel Ph.D.

Co-Founder, President & CEO

Mr. Christopher Cozic

Executive VP & Chief People Officer

Dr. Judith V. Klimovsky M.D.

Executive VP & Chief Development Officer

Dr. Martine J. van Vugt Ph.D.

Executive VP & Chief Strategy Officer

Mr. Martin Schultz

Senior Director, Head of Development Business Partnership & Strategy and Director

Dr. Tahamtan Ahmadi M.D., Ph.D.

Executive VP, Chief Medical Officer & Head of Experimental Medicines

Mr. Anthony Pagano CPA

Executive VP & CFO

Mr. Rayne Waller

Executive VP & Chief Technical Operations Officer

Mr. Gregory David Emil Mueller

Executive VP, General Counsel & Chief Legal Officer

FAQs

What is Genmab A/s share price today?

Genmab A/s share price today is $27.98 as on at the close of the market. Genmab A/s share today touched a day high of $28.16 and a low of $27.59.

What is the 52 week high and 52 week low for Genmab A/s share?

Genmab A/s share touched a 52 week high of $35.43 on and a 52 week low of $17.24 on . Genmab A/s stock price today i.e. is closed at $27.98,which is 21.03% down from its 52 week high and 62.34% up from its 52 week low.

What is Genmab A/s's market capitalisation today?

Genmab A/s market capitalisation is $0.02T as on .

How to invest in Genmab A/s Stock (GMAB) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Genmab A/s on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Genmab A/s Shares that will get you 0.0536 shares as per Genmab A/s share price of $27.98 per share as on March 11, 2026 at 1:29 am IST.

What is the minimum amount required to buy Genmab A/s Stock (GMAB) from India?

Indian investors can start investing in Genmab A/s (GMAB) shares with as little as ₹91.833 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹918.33 in Genmab A/s stock (as per the Rupee-Dollar exchange rate as on ). Based on Genmab A/s share’s latest price of $27.98 as on March 11, 2026 at 1:29 am IST, you will get 0.3574 shares of Genmab A/s. Learn more about fractional shares .

What are the returns that Genmab A/s has given to Indian investors in the last 5 years?

Genmab A/s stock has given -15.53% share price returns and 26.32% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?